Concentrated Bone Marrow Aspirate May Decrease Postoperative Cyst Occurrence Rate in Autologous Osteochondral...

Area of Science:

• Orthopedic Surgery
• Regenerative Medicine
• Sports Medicine

Background:

• Osteochondral lesions of the talus often require surgical intervention.
• Autologous osteochondral transplantation (AOT) is a common treatment for talar osteochondral defects.
• The use of concentrated bone marrow aspirate (CBMA) as an adjunct to AOT is being investigated to improve outcomes.

Purpose of the Study:

• To compare the efficacy of AOT with and without CBMA in treating osteochondral lesions of the talus.
• To evaluate the impact of CBMA on postoperative functional and MRI outcomes.
• To assess CBMA's ability to reduce postoperative cyst formation after AOT.

Main Methods:

• Retrospective analysis of 59 patients undergoing AOT between 2004 and 2008.
• Patients were divided into AOT with CBMA (n=28) and AOT alone (n=26) groups.
• Clinical outcomes assessed using FAOS and SF-12; MRI evaluated with MOCART score and cyst formation.

Main Results:

• Both groups showed significant functional improvement (FAOS, SF-12), with no difference between groups.
• No significant difference in mean MOCART scores between the AOT/CBMA and AOT-alone groups (80.4 vs 84.3).
• The AOT/CBMA group had a significantly lower rate of cyst formation (46.4% vs 76.9%, P=.022).

Conclusions:

• CBMA significantly reduces postoperative cyst formation following AOT for talar osteochondral lesions.
• CBMA does not lead to significant differences in medium-term functional outcomes or MRI-assessed cartilage repair (MOCART score).
• Further research may explore long-term effects and optimal techniques for CBMA application in AOT.